Astria Therapeutics, Inc. (ATXS) Misses Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ATXS Hot Sheet
Join SI Premium – FREE
Astria Therapeutics, Inc. (NASDAQ: ATXS) reported Q3 EPS of ($0.55), $0.13 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $706 thousand versus the consensus estimate of $12.8 million.
For earnings history and earnings-related data on Astria Therapeutics, Inc. (ATXS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbnb (ABNB) call put ratio 1 call to 1.3 puts into quarter results
- NamSys Announces Normal Course Issuer Bid
- Enphase Energy (ENPH) June 25 puts active, share price up 9.5%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
